Overview
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
Status:
Completed
Completed
Trial end date:
2021-05-14
2021-05-14
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe diseasePhase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Cambridge Health AllianceTreatments:
AcetylcysteineN-monoacetylcystine
Criteria
Inclusion Criteria:- known or suspect COVID-19 disease AND one or more of the following influenza-like
symptoms, including: diarrhea vomiting fever (subjective or measured) chills myalgias
fatigue sore throat headache cough nasal/sinus congestion or rhinorrhea shortness of
breath chest pain
Exclusion Criteria:
- Minors, pregnant women and people unable to provide informed consent are excluded from
this study